Replimune Group (NASDAQ:REPL) Trading 3.8% Higher Following Analyst Upgrade

Replimune Group, Inc. (NASDAQ:REPL)’s stock price rose 3.8% on Wednesday after JPMorgan Chase & Co. raised their price target on the stock from $14.00 to $17.00. JPMorgan Chase & Co. currently has an overweight rating on the stock. Replimune Group traded as high as $11.50 and last traded at $11.49. Approximately 89,276 shares were traded during trading, a decline of 92% from the average daily volume of 1,124,411 shares. The stock had previously closed at $11.07.

A number of other equities research analysts have also weighed in on REPL. Roth Capital upgraded shares of Replimune Group to a “strong-buy” rating in a report on Tuesday, August 27th. Barclays lifted their price target on shares of Replimune Group from $13.00 to $17.00 and gave the company an “overweight” rating in a research note on Friday, June 7th. HC Wainwright reissued a “buy” rating and issued a $17.00 price objective on shares of Replimune Group in a research note on Monday, September 16th. Wedbush restated an “outperform” rating and set a $16.00 price objective on shares of Replimune Group in a report on Thursday, June 6th. Finally, Roth Mkm assumed coverage on Replimune Group in a report on Tuesday, August 27th. They issued a “buy” rating and a $17.00 target price for the company. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $16.80.

Insider Activity

In related news, CFO Emily Luisa Hill sold 8,938 shares of the firm’s stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $10.18, for a total transaction of $90,988.84. Following the sale, the chief financial officer now owns 101,057 shares of the company’s stock, valued at $1,028,760.26. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 20.60% of the company’s stock.

Hedge Funds Weigh In On Replimune Group

Several institutional investors and hedge funds have recently bought and sold shares of REPL. Nisa Investment Advisors LLC increased its position in Replimune Group by 10,304.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company’s stock valued at $45,000 after buying an additional 4,946 shares in the last quarter. Point72 DIFC Ltd purchased a new position in shares of Replimune Group in the 2nd quarter valued at approximately $57,000. Quest Partners LLC acquired a new stake in Replimune Group in the 4th quarter worth approximately $76,000. Diversified Trust Co acquired a new stake in Replimune Group in the 1st quarter worth approximately $94,000. Finally, China Universal Asset Management Co. Ltd. grew its position in Replimune Group by 72.8% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 11,808 shares of the company’s stock worth $96,000 after purchasing an additional 4,975 shares during the last quarter. 92.53% of the stock is owned by hedge funds and other institutional investors.

Replimune Group Price Performance

The stock’s 50 day simple moving average is $10.31 and its 200-day simple moving average is $8.50. The firm has a market cap of $760.40 million, a price-to-earnings ratio of -3.44 and a beta of 1.22. The company has a debt-to-equity ratio of 0.16, a quick ratio of 13.46 and a current ratio of 13.46.

Replimune Group (NASDAQ:REPL) last released its earnings results on Thursday, August 8th. The company reported ($0.78) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.88) by $0.10. Equities research analysts anticipate that Replimune Group, Inc. will post -3.11 EPS for the current fiscal year.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.